• Molecular NameOlmesartan
  • SynonymDE-092; Olmesartan medoximil; Olmesartan medoxomil
  • Weight558.595
  • Drugbank_IDDB00275
  • ACS_NO144689-63-4
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.25
  • pkaN/A
  • LogD (pH=7, predicted)0.46
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-4.92
  • LogSw (predicted, AB/LogsW2.0)0.06
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors2
  • No.of HBond Acceptors12
  • No.of Rotatable Bonds11
  • TPSA154.34
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn angiotensin II receptor antagonist used to treat high blood pressure.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability26.0
  • Protein binding99.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmFollowing the rapid and complete conversion of olmesartan medoxomil to olmesartan during absorption, there is virtually no further metabolism of olmesartan.
  • Half life13 h
  • ExcretionRenal 40%, biliary 60%
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityIn placebo-controlled trials, the only adverse event that occurred in more than 1% of patients treated with olmesartan medoxomil and at a higher incidence versus placebo was dizziness (3% vs. 1%).
  • LD50 (rat)N/A
  • LD50 (mouse)N/A